GlassScriptPhysician profile
Christopher J Rodgman
NPI 1861635849
$2,997.39
in general payments reported to CMS, 2019-2025
18 companies · $200 in 2025
The $200 reported for 2025 was more than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $91.63 · 2020: $12.89 · 2022: $342 · 2023: $2,047 · 2024: $304 · 2025: $200.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,345 · Consulting Fee: $200 · Education: $5.89.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,345.18 |
| Consulting Fee | $200.00 |
| Education | $5.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $423.06 | 2019-2024 | Ingrezza |
| Abbvie INC. | $379.94 | 2023-2024 | Vraylar |
| Janssen Pharmaceuticals, INC | $364.77 | 2022-2024 | Spravato, Invega Sustenna, Invega |
| Alkermes, INC. | $311.24 | 2019-2024 | Aristada, Lybalvi, Vivitrol |
| Teva Pharmaceuticals USA, INC. | $304.61 | 2022-2023 | Austedo, Austedo Xr, Ajovy |
| Otsuka America Pharmaceutical, INC. | $267.75 | 2019-2023 | Rexulti, Abilify Asimtufii, Nuedexta |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $228.79 | 2022-2023 | |
| Janssen Scientific Affairs, LLC | $200.00 | 2025 | Spravato |
| Axsome Therapeutics, INC. | $194.99 | 2023-2024 | Auvelity |
| Lundbeck LLC | $85.24 | 2022-2023 | Abilify Maintena, Rexulti |
| Takeda Pharmaceuticals U.S.A., INC. | $64.40 | 2022-2023 | Trintellix |
| Indivior INC. | $48.27 | 2023-2024 | Sublocade |
| Sunovion Pharmaceuticals INC. | $26.68 | 2022 | |
| Acadia Pharmaceuticals INC | $23.85 | 2022 | |
| Corium, LLC | $21.82 | 2023 | Azstarys |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Braeburn INC. | $20.29 | 2024 | Brixadi |
| Tris Pharma INC | $18.00 | 2023 | Dyanavel Xr |
| Ironshore Pharmaceuticals INC. | $13.69 | 2023 | Jornay Pm |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Rodgman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.